← Back to Blog|Fundraising
Fundraising2 min read9/9/2024

Candid Therapeutics Raises $370M in Series A

Candid Therapeutics, a Biotech company based in San Francisco, CA, has raised $370M in Series A at a $1.2B valuation led by Venrock, Fairmount, TCGX.

FNT

Fundraising News Team

Published on 9/9/2024

Candid Therapeutics Raises $370M in Series A


Candid Therapeutics Raises $370M in Series A

Candid Therapeutics has successfully raised $370M in a Series A at a $1.2B valuation led by Venrock, Fairmount, TCGX.

Company Overview

Candid Therapeutics is a Biotech company headquartered in San Francisco, CA, founded in 2023 with 70+ employees.

Developing novel therapeutics for autoimmune diseases

Fundraising Details

- Amount Raised: $370M
- Round Type: Series A
- Valuation: $1.2B
- Date: 2024-09-09
- Investors: Venrock, Fairmount, TCGX

About Candid Therapeutics

Developing novel therapeutics for autoimmune diseases The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

- Headquarters: San Francisco, CA
- Founded: 2023
- Team Size: 70+
- Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in Candid Therapeutics's vision and execution. The capital will likely be used to:

- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Candid Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone

Reaching a $1.2B valuation marks an important milestone for Candid Therapeutics, positioning the company among notable players in the Biotech industry.


Looking Ahead

With this new capital, Candid Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

---

This fundraising news was reported on 2024-09-09. For more information about Candid Therapeutics, visit their headquarters at San Francisco, CA.

Share this article:

Related Articles

More insights from our Fundraising experts

Archive Intel Raises $6.3M in Series A
Fundraising2 min read

Archive Intel Raises $6.3M in Series A

Archive Intel, a Fintech company based in New York, NY, has raised $6.3M in Series A led by Gray Line Partners.

FNT

Fundraising News Team

10/6/2025

Upfront Raises $10M in Pre-Seed
Fundraising2 min read

Upfront Raises $10M in Pre-Seed

Upfront, a Fintech company based in Dubai, UAE, has raised $10M in Pre-Seed led by Palm Ventures, SABAH.fund.

FNT

Fundraising News Team

10/5/2025

Naveen Rao AI Hardware Raises $400M in Series A
Fundraising2 min read

Naveen Rao AI Hardware Raises $400M in Series A

Naveen Rao AI Hardware, a AI/ML company based in San Francisco, CA, has raised $400M in Series A at a $5B valuation led by Andreessen Horowitz, Lightspeed.

FNT

Fundraising News Team

10/3/2025

Ready to Transform Your Sales Process?

Join thousands of sales professionals who trust Salestools AI to drive results.

Start Free Trial